EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W Valle, Chigusa Morizane, Thomas B Karasic, Thomas A Abrams, Junji Furuse, Robin K Kelley iD, Philippe A Cassier, Heinz-Josef Klümpen, Heung-Moon Chang und 19 weitere

New England Journal of Medicine · 19.01.2023 · 388 (3) · 228-239

DOI: 10.1056/nejmoa2206834 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 19.01.2023. Verfasst von Lipika Goyal und 30 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of Cali…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Cholangiocarcinoma, Protein Kinase Inhibitors. Die Arbeit wurde bisher 644-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsBile Ducts, IntrahepaticCholangiocarcinomaProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2Antineoplastic AgentsAgedHumansQuality of LifePyrazolesPyrimidinesPyrroles

Substanzen

Protein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2Antineoplastic AgentsFGFR2 protein, humanfutibatinibPyrazolesPyrimidinesPyrroles

Autor:innen und Institutionen

  • From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) - both in California; th…

ORCID-Profile: Robin K Kelley, Karim A Benhadji

Förderung

  • Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd.

Zitieren

APA

Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., Klümpen, H. J., Chang, H. M., Chen, L. T., Tabernero, J., Oh, D. Y., Mahipal, A., Moehler, M., Mitchell, E. P., Komatsu, Y., …, & FOENIX-CCA2 Study Investigators (2023). Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma. New England Journal of Medicine, 388(3), 228-239. https://doi.org/10.1056/nejmoa2206834

Vancouver

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma. New England Journal of Medicine. 2023;388(3):228-239. doi:10.1056/nejmoa2206834

BibTeX
@article{Goyal2023,
  author = {Goyal, Lipika and Meric-Bernstam, Funda and Hollebecque, Antoine and Valle, Juan W and Morizane, Chigusa and Karasic, Thomas B and Abrams, Thomas A and Furuse, Junji and Kelley, Robin K and Cassier, Philippe A and Klümpen, Heinz-Josef and Chang, Heung-Moon and Chen, Li-Tzong and Tabernero, Josep and Oh, Do-Youn and Mahipal, Amit and Moehler, Markus and Mitchell, Edith P and Komatsu, Yoshito and Masuda, Kunihiro and Ahn, Daniel and Epstein, Robert S and Halim, Abdel-Baset and Fu, Yao and Salimi, Tehseen and Wacheck, Volker and He, Yaohua and Liu, Mei and Benhadji, Karim A and Bridgewater, John A and FOENIX-CCA2 Study Investigators, FOENIX-CCA2 Study Investigators},
  title = {Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {3},
  pages = {228--239},
  doi = {10.1056/nejmoa2206834}
}
Kostenlos starten →